There is limited literature on Mycobacterium abscessus infections in children and limited data about its diagnosis and management. The incidence of infections due to M abscessus appears to be increasing in certain populations and can be a significant cause of morbidity and mortality.
There is sparse literature on Mycobacterium abscessus infections in children and limited data about its diagnosis and management. Most published cases have been pulmonary infections in children with cystic fibrosis (CF) and catheter-associated blood stream infections in immunocompromised hosts. This review summarizes the literature on pediatric M abscessus infections and identifies current gaps in knowledge. However, given the limited pediatric data, adult data have been used when there are limited pediatric data.
MICROBIOLOGY
Mycobacterium abscessus is classified as a rapidly growing nontuberculous mycobacterium (NTM), forming mature colonies on solid media within 7 days [1] . It frequently can be isolated in liquid media in 2-5 days. Historically classified into Runyon groups, NTM are now identified using rapid molecular techniques [2] . Until 1992, M abscessus was classified as a subspecies of Mycobacterium chelonae [3] . Based on deoxyribonucleic acid sequence differences in the rpob and erm (41) genes, M abscessus is now a separate species with 3 subspecies: M abscessus subsp abscessus, M abscessus subsp massiliense, and M abscessus subsp bolletii [4, 5] . Patient care often requires identification of this pathogen to the subspecies level because of differences in antimicrobial susceptibilities to the macrolides affecting clinical outcomes [6] . Patients with M abscessus subsp massiliense generally have better clinical outcomes because the functional erm (41) gene that causes inducible resistance to macrolides occurs only in subspecies abscessus and bolletii [3, 7] . Subspecies massiliense has a large deletion in its erm (41) gene that inactivates the gene, resulting in all untreated isolates being macrolide susceptible [8] . The difference in outcomes appears to relate exclusively to the presence or absence of susceptibility to oral macrolides. Resistance to clarithromycin can be detected by either susceptibility testing or by sequencing of the erm (41) gene. The Clinical and Laboratory Standards Institute (CLSI) has adopted a 14-day incubation period for clarithromycin before reading the minimum inhibitory concentration to allow for erm (41) gene induction by the clarithromycin [9] . In addition to presence of a functional erm (41) gene, 23S mutations at positions 2058 and 2059 predict resistance to and treatment failure for macrolides [10] [11] [12] . Resistance to both intravenous (IV) and nebulized amikacin can occur due to 16S ribosomal mutations [10, 13, 14] .
EPIDEMIOLOGY
Mycobacterium abscessus is ubiquitous in the environment, found in water and soil [3, 15] . Although M abscessus infections occur throughout the United States, they are most common in the Southeastern states ranging from Florida to Texas [16, 17] . Mycobacterium abscessus was first recognized as a human pathogen in the 1950s. The incidence of infections appears to be increasing in most areas of the world, with a particularly high incidence in Taiwan and Korea [18] . However, the exact incidence and prevalence of NTM infections are not known because they are not routinely reported to health authorities [19] .
Although there are some known risk factors for development of disease, data on the epidemiology and mechanisms of transmission of M abscessus to children are limited [20] . Children at increased risk for development of disease caused by M abscessus include those with the following: tympanostomy tubes; central venous catheters; CF and other chronic lung diseases, usually associated with underlying bronchiectasis; Mendelian susceptibility to mycobacterial disease; and children with other immune defects, especially those involving lymphocytes [20, 21] . Adults receiving anti-tumor necrosis factor (TNF)-α therapy are also at increased risk, but there are no comparable data for children [22] . Adult patients in Taiwan with rheumatoid arthritis have a 6.24-fold higher risk of NTM disease compared with the general population [23] . In the United States, there have been at least 105 confirmed cases of NTM disease secondary to anti-TNF-α therapy, with 12 cases in adults caused by M abscessus [22] . The most common clinical presentation of M abscessus infection has been pulmonary disease (in the setting of CF as the most common clinic presentation) followed by skin and soft tissue infection, central line-associated blood stream infections, especially in oncology and hematopoietic stem cell transplant patients, chronic otitis media associated with tympanostomy tubes, bone or joint infection, and disseminated disease. Adults who have had previous disease caused by Mycobacterium tuberculosis are at increased risk for developing M abscessus pulmonary disease, although this has not been reported in children, partly because there are limited data on epidemiology and clinical manifestations of M abscessus in children in countries with a high prevalence of tuberculosis [20] .
TRANSMISSION, INFECTION CONTROL, AND PREVENTION
Transmission of M abscessus can occur via inhalation, ingestion, or direct contact with an environmental source or fomite [1] . Environmental sources are soil and water, including tap water and healthcare water systems [24] . In a study of water sources in Brisbane, Australia, M abscessus was isolated from 10 different locations including from potable water, a rainwater tank, a swimming pool, and domestic taps [25] . In addition, in a study of household water and shower aerosols of patients with NTM pulmonary disease, 7 patients had pulmonary disease due to M abscessus; of these, 3 cases had the same species isolated from a home water source [26] . Healthcare-associated transmission was first described in 1938, and it currently remains an important source of disease, usually associated with surgical wounds, implanted catheters, and medical devices [3, 27] . Outbreaks of M abscessus in adults in have been associated with cosmetic procedures and acupuncture therapy [15, [28] [29] [30] . There also have been recent clusters of M abscessus pediatric odontogenic infections after pulpotomy caused by contaminated tap water used during the procedures. In Georgia, 29 children developed odontogenic infections, and in Orange County, California, there were 22 confirmed and 51 probable cases of oral cellulitis after pulpotomy [31, 32] . Patients with indwelling catheters should avoid contact of the catheter and wounds with tap water, because M abscessus has been isolated from indwelling devices including ventriculoperitoneal shunts and central venous catheters [1, 24, 33, 34] . Mycobacterium abscessus can develop in biofilms and grow in very high temperatures, making treatment, decontamination, and eradication very difficult [24, 35] .
Some molecular epidemiology studies of patients with CF have suggested possible human-to-human transmission of M abscessus, although other studies have not [36] [37] [38] [39] [40] . A whole-genome sequencing study conducted in the United Kingdom (UK) on adult patients with CF demonstrated clusters of nearly identical isolates of subspecies massiliense; because an environmental source could not be identified, the authors thought this could represent person-to-person transmission [37] . A similar study analyzing M abscessus infections in pediatric patients with CF in London demonstrated little evidence to suggest transmission from patient-to-patient [39] . However, large sequencing studies have identified possible transcontinental clustering, demonstrating infections due to highly related strains of M abscessus subsp massiliense in CF patients in the UK and United States, as well as in skin and soft tissue infections in Brazil [41, 42] . A sequencing study using a collection of isolates from Europe, the United States, Brazil, Malaysia, China, and South Korea demonstrated clades of nearly identical isolates in these geographically diverse locations, suggestive of widespread transmission [38] . Although it is unclear how transmission occurs, there is evidence for likely fomite and aerosol transmission. In a multicenter international study, 3 separate transmission events associated with surface contamination were detected, and cough aerosols produced by an infected patient generated long-lived particles, indicating a potential for airborne transmission [37] .
The most specific infection control measures have been recommended for patients with CF by the Cystic Fibrosis Foundation [43, 44] . For the outpatient clinical setting, patients with CF and M abscessus should minimize time in common areas and should be segregated from other patients with CF. In the hospital setting, patients should be on contact and droplet precautions in well ventilated, single patient rooms. However, there is insufficient evidence for the use of airborne precautions. Patients should use their own equipment whenever possible, and hospital equipment should be disinfected, cleaned, and dried before use by another patient. More specific infection control measures have been implemented after concerns for local outbreaks of M abscessus pulmonary disease. After identifying multiple patients with M abscessus pulmonary disease, an adult CF clinic performed an outbreak investigation and implemented the following control measures: education of the patients, family members, and providers on proper hand hygiene, personal protective equipment, and the need to avoid other patients with CF; scheduling of colonized patients for the last clinic appointment of the day; utilization of airborne isolation rooms; and sterilization of the clinic room 4 times after use by patients colonized with M abscessus [45] . After an outbreak of M abscessus in 5 children in a pediatric ICU, similar infection control measures were implemented and additional actions were as follows: reinforcing of hand hygiene and contact precautions, environmental cleaning with hot water and hypochlorite solution was performed, and closure of the Pediatric Intensive Care Unit to new admissions. One year after these interventions, no further cases were identified [46] .
CLINICAL MANIFESTATIONS
Mycobacterium abscessus in both adults and children has been associated with a wide variety of clinical manifestations including the following: pulmonary infections; chronic otitis media; lymphadenitis; central line-associated blood stream infections, especially in oncology and hematopoietic stem cell transplant patients; and skin and soft tissue infections in both immune compromised and normal host children [20, 21, [47] [48] [49] . Although clinical presentations do not vary by subspecies, clinical outcomes appear to be related to the specific subspecies causing infection. Several studies in adults without CF have demonstrated improved rates of clearance of pulmonary infections for those infected with subspecies massiliense compared with those infected with subspecies abscessus, despite similar clinical and radiographic findings and similar treatment regimens, due to the susceptibility of subspecies massiliense and resistance of subspecies abscessus to clarithromycin [6, 50, 51] . Ultimately, the course and prognosis of disease are dependent most importantly on the drug susceptibilities of the isolate, particularly to the macrolides and amikacin, and on the underlying immune system of the host [7, 52] .
Pulmonary Infections

Patients With Cystic Fibrosis
The number of NTM infections in patients with CF appears to be increasing, with a prevalence of 6%-13% [1, 35, [53] [54] [55] [56] [57] . Mycobacterium abscessus and Mycobacterium avium-complex are the most common species [54] . In an 8-year multicenter study conducted on 1200 adults and children with CF, 11% of patients grew NTM from respiratory cultures and 55.6% were M abscessus [58] . The apparent increase in the prevalence of NTM infections in general, and M abscessus in particular, is incompletely understood [53, 55, 57] . In a cross-sectional study including approximately 10% of CF patients in the United States age 10 years and older, those with M abscessus were older and had less significantly severe lung disease and lower rates of infection with Pseudomonas aeruginosa compared with other patients with CF [59, 60] . In contrast, a 2-year cross-sectional study consisting of 186 CF patients in Israel found that patients with NTM had lower forced expiratory volume in 1 second (FEV 1 ), and higher rates of P aeruginosa infection compared with controls [54] . Mycobacterium abscessus infection is seen in all childhood age groups, with a peak incidence between ages 11 and 15 years and an increase in prevalence with age, from 10% in children age 10 years to >30% in adults [43, 53] . There is some evidence for an association between NTM disease and allergic bronchopulmonary aspergillosis [53, 61] . Whether longterm use of macrolides leads to increased rates of M abscessus infection is unclear, with some studies in adults demonstrating increased rates [62] whereas others suggest long-term use may actually protect against infection [63] . The impact of systemic corticosteroid use on development of NTM pulmonary disease is also unclear, with some evidence suggesting a protective effect and other studies demonstrating a predisposition towards infection; however, these studies are not specific to M abscessus [61, [64] [65] [66] .
Mycobacterium abscessus has emerged as a major respiratory pathogen leading to an accelerated lung function decline in patients with CF due to inflammatory lung damage [58, [67] [68] [69] . Clinical symptoms consistent with pulmonary disease secondary to infection with M abscessus in both adults and children include the following: decline in FEV 1 , increased cough with sputum production or hemoptysis, and fever or weight loss after other common comorbidities have been excluded or adequately treated [1] . In addition to clinical symptoms, diagnosis requires radiographic features consistent with NTM pulmonary disease. In a retrospective review of patients with CF and M abscessus pulmonary disease, the most common findings on chest radiograph were patchy bilateral reticulonodular opacities, followed by lobar volume decrease, upper lobe consolidation, and unilateral cavitary lesions. However, plain film radiographic findings are nonspecific, and a high-resolution computed tomography (CT) scan should be obtained. The most common CT scan findings in adults include nodules, cavitations, tree-in-bud opacities, focal consolidation, and bronchiectasis [1, 50, 70] .
Per the Cystic Fibrosis Foundation guidelines, cultures for NTM should be obtained at least annually [43, 53] . When investigating for M abscessus pulmonary disease, antibiotics with activity against mycobacteria, such as macrolides, fluoroquinolones, and aminoglycosides, should be discontinued before sputum collection [53] . The diagnosis of pulmonary disease caused by M abscessus requires the exclusion of other causative infections, the presence of positive cultures obtained on 2 separate occasions from expectorated sputum or a single positive culture from bronchoalveolar lavage or transbronchial/lung biopsy, and consistent clinical and radiographic findings ( Figure 1 ) [1, 53] . Patients with CF who have M abscessus isolated from respiratory secretions are more likely to meet American Thoracic Society/Infectious Diseases Society of America criteria for diagnosis of NTM pulmonary disease than those with other NTM [53, 60, 67] .
Pulmonary disease with M abscessus in patients with CF after lung transplantation is associated with increased morbidity and mortality [71, 72] . Patients have developed skin infections and abscesses posttransplant despite antimycobacterial therapy [71] . However, in a case series of lung transplantation in 5 patients with positive pretransplant cultures for M abscessus, 4 patients survived, indicating that the presence of M abscessus should not be considered an absolute contraindication to lung transplantation [43, 53] .
Pulmonary Infections in Other Populations
Although exact numbers are not known, the estimated incidence of respiratory infections in adults caused by NTM in general, and M abscessus in specific, appears to be increasing. Available data suggest that underlying lung pathology is the greatest risk factor. The most common underlying lung pathology associated with NTM infections is bronchiectasis, with one study demonstrating a frequency of NTM infections in this population of 37% [66] . In a case series of 5 children in Kuwait with underlying chronic comorbidities, including cardiovascular and lung disease, every patient developed increased respiratory secretions with pulmonary infiltrates and one developed septicemia [46] . Adults who have had pulmonary tuberculosis are at increased risk for developing M abscessus pulmonary disease, but this has not been reported in children [20] .
Mycobacterium abscessus lung disease is rare in immunocompetent children without other lung pathology [73] . The clinical and radiographic manifestations are similar to those of other mycobacterial infections. There are 2 published case reports of immunocompetent children with NTM endobronchial disease, and 41 children with pulmonary parenchymal disease, although none of these were culture-confirmed M abscessus infections [73] . In a review of adult patients with bronchiectasis without CF, patients with NTM infections had mild symptoms including cough, fever, fatigue, and weight loss [74] . The prognosis for children without CF appears to be very good with most achieving full resolution of disease. The radiographic and clinical features are similar to pulmonary tuberculosis in children, and some children with NTM pulmonary disease undoubtedly get treated for tuberculosis.
In addition to those with CF, pediatric patients at risk for pulmonary disease with M abscessus include those with (1) ciliary dyskinesia and (2) neuromuscular disorders requiring tracheostomy [75] . Immunocompromising conditions predisposing adults to pulmonary infections with M abscessus include the following: malignancies; hematopoietic stem cell transplantation; therapy with anti-TNF-α medications; and rare inherited defects in the signal transducer and activator of transcription 1 (STAT1), interferon (IFN)-γ, and interleukin-12 pathways [22, [76] [77] [78] .
Skin and Soft Tissue Infections
Clinical manifestations of skin and soft tissue infections caused by M abscessus in adults and children include the following: subcutaneous nodules, abscesses, cellulitis, ulcers, and sinus tracts [79] [80] [81] [82] . Immunocompromised adults can also present with lymphadenopathy and systemic symptoms such as single or multiple disseminated lesions secondary to metastatic spread, septic shock, pulmonary infiltrates, adrenal necrosis, and meningitis [82, 83] . Skin lesions in immunocompetent hosts are usually localized to the site of inoculation. Infection in adults and children typically occurs after skin injury due to trauma or surgery, but it also can be related to catheter entry sites [3, 83, 84] . Healthcare-associated infections have occurred after medical needle injections such as vaccinations, cosmetic procedures, and acupuncture [16, 28, [85] [86] [87] [88] [89] . Cutaneous infections in immunocompetent children have been reported secondary to swimming or wading in a contaminated pond or public swimming pool. One of the pools was chlorinated, whereas the chlorination status of the pool associated with an outbreak in Italy was not documented [80, 81, 90] .
Lymphadenitis
Cervicofacial lymph node infections due to NTM in otherwise healthy children under the age of 5 years have been well documented, with a prevalence ranging from 3.1 to 77 per 100 000 in Europe [91, 92] . However, there are limited data specific to M abscessus lymphadenitis in children. From our own institution's recent experience of several cases, the clinical presentation of M abscessus lymphadenitis is similar to infection with other species of NTM: a slow-growing lymph node with overlying erythema or violaceous hue. There was a healthcare-associated outbreak secondary to contaminated tap water used at a regional dental clinic in Georgia in which 12 pediatric patients developed mandibular osteomyelitis and 8 developed submandibular and/ or cervical lymphadenitis. The 8 patients with lymphadenitis underwent excision of the involved nodes, 4 of whom were deemed to have inadequate surgical debridement and were treated with combination antimycobacterial therapy [50] ; all 8 patients had resolution of disease. There are 2 other reported cases of lymphadenitis in children: a 6-year-old male with submandibular lymphadenitis that resolved with antimycobacterial therapy alone, and a single patient identified in a 2-year prospective study of NTM infections in children in the Netherlands [91, 92] . Presenting symptoms for these few cases included face and neck swelling, a tender nonmobile mass with overlying erythema, and purulent discharge. The optimal medical therapy is unstudied, although a combination of surgical management, as well as multidrug therapy, likely should be used. Surgical resection may speed recovery and possibly improve cosmetic outcomes for M abscessus lymphadenitis, although outcome data are scarce. Regardless of the extent of surgical debridement, combination antimycobacterial therapy should always be used.
Bloodstream Infections
Bloodstream infections with M abscessus most commonly occur in immunocompromised patients, including those with diabetes, end-stage renal disease, prolonged corticosteroid usage, or cancer [93] . Patients typically present with fever in the setting of an indwelling central venous catheter, but bloodstream infections also have been associated with surgical wound infections and ventricular shunts [3, 70, 88] .
There are several reports of oncology patients with catheter-associated bloodstream infections with M abscessus [76, [94] [95] [96] [97] . A pediatric oncology study conducted at St. Jude Children's Research Hospital found an incidence rate of bacteremia with rapidly growing NTM of 0.4/100 000 cases. Five of the 27 cases were due to M abscessus, and 4 of the 5 were associated with a central venous catheter [97] . Most patients with catheter-associated bloodstream infections due to M abscessus have good clinical outcomes with immediate removal of the intravascular catheter and appropriate antimicrobial therapy [92] .
Central Nervous System Infections
Central nervous system (CNS) infections due to M abscessus are rare, with only 14 reported cases [34, 35, [98] [99] [100] [101] [102] . Central nervous system infections typically occur secondary to neurosurgical procedures, indwelling prosthetic devices, or via hematogenous dissemination or direct extension from a wound [93] [94] [95] [96] . There are 3 reported cases of ventriculoperitoneal (VP) shunt-associated infections [33, 34, 98] . We recently cared for a patient with a VP shunt infection that required 2 months of intraventricular amikacin in addition to 3 intravenous antibiotics to sterilize the cerebrospinal fluid (CSF). All other reported cases have been in adults and have been associated with history of trauma with a knife, an infected ocular prosthesis, endocarditis, intracranial catheters, neurologic procedures, or otolaryngological disease [99] [100] [101] [102] . The most common presentations have been meningitis and cerebral abscesses [3] . Patients with CNS infections caused by M abscessus often have subacute presentations developing over several weeks, and symptoms include progressive headache, neck pain/stiffness, nausea, emesis, fever, weight loss, difficulty with concentration, anorexia, lethargy, altered mental status, seizures, facial droop, muscular weakness, diplopia, and drainage from a VP shunt tract [33, 34, [99] [100] [101] [102] . Other complications of CNS infection due to M abscessus include development of subdural empyema and septic cerebral thrombophlebitis [94, 102] .
Cerebrospinal fluid evaluation typically reveals features consistent with bacterial meningitis, including low glucose, high protein, and an elevated white blood cell count [101] . Brain imaging can reveal meningeal enhancement, ventricular enlargement, abscesses, and hemorrhage [33, [100] [101] [102] .
Mortality rates from M abscessus CNS infection are high, particularly in immunocompromised patients [99] . The largest case series of CNS infections due to M abscessus comes from Taiwan; 3 of 8 patients identified in this series died [99] .
Dental Infections
As described previously, there have been 2 reported outbreaks of odontogenic infections with M abscessus after pulpotomy of primary teeth using tap water in Georgia and California [31, 32, 49] . Although the use of sterile, distilled water is routine for root canal procedures in adults, tap water is frequently used for pulpotomy of primary teeth in children. These outbreaks occurred in children aged 2-11 years old. Clinical manifestations included facial and neck swelling, lymphadenopathy, fever, pain, mandibular osteomyelitis, and pulmonary nodules. All patients required hospitalization for IV antimycobacterial therapy, with many patients requiring extensive surgical excision [31, 32, 49] . Although all patients were ill, there were no deaths. Diagnosis was made based on biopsy showing granulomatous inflammation and isolation of M abscessus.
Ocular Infections
There has been an apparent increase in the incidence of M abscessus ocular infections over the past decade. The majority of data on ocular infections due to M abscessus come from adults, although there are limited data on pediatric patients. In a review of 100 isolates of NTM associated with ocular infections, using molecular identification, 38% of these infections were due to M abscessus [103] . Risk factors for development of ocular infection include use of contact lenses, trauma, and recent surgery [103, 104] . Ocular infection with M abscessus can have a variety of clinical manifestations including keratitis, caniculitis, dacrocystitis, scleritis, endophthalmitis, and implant infections [103, 105, 106] . Presentation is typically subacute, lasting several weeks before presentation for medical care. Symptoms of ocular infections with M abscessus include periorbital swelling and erythema, erythematous nodules with purulent discharge, eye pain and discharge, proptosis, restricted ocular motility and vision loss [105, 106] . Any of the following may be seen on ophthalmologic exam: epithelial defects, hypophyon; infiltrates of the cornea, corneal melting, scleral thinning, and granulomatous inflammation [105, 106] .
In a study of M abscessus ocular infections reported from Taiwan, all patients presented with significant vision loss, with only 50% of patients having visual improvement after treatment. All patients were treated with antimycobacterial therapy, and the majority required adjunctive surgical therapy for clearance of infection [105] .
MANAGEMENT
Diagnosis of infection by M abscessus requires isolation of the organism. Based on expert opinion, the primary management of M abscessus infections should be combination antimycobacterial therapy. In addition, surgical therapy should be considered an important adjunct of management when debridement of diseased tissue can be performed. Given that M abscessus is frequently resistant to many antimicrobials, combination therapy with at least 2 or 3 effective antibiotics should be used. Unfortunately, there have been no randomized controlled trials to guide optimal therapy; therefore, most treatment recommendations are based on expert opinion. For the antituberculous agents, there is poor correlation between in vitro drug susceptibility results and clinical outcomes. For clarithromycin, the presence of a functional erm(41) gene predicts inducible resistance and treatment failure. In addition, 23S mutations at positions 2058 and 2059 also predict resistance and treatment failure to macrolides, and 16S ribosomal mutations can lead to resistance to amikacin [10] [11] [12] [13] [14] . To protect macrolides and amikacin from developing mutational resistance, multidrug therapy should always be used to treat these infections.
Antimicrobial Therapy: General Principles
Selection of antimycobacterial therapy should depend on the site of infection and antimicrobial susceptibilities. Based on expert opinion, medical management should rely on a combination of 2 or 3 antimycobacterial medications [3] . Mycobacterium abscessus also can have inducible resistance to macrolides, although this is dependent on the presence of a functional erm (41) gene. Resistance to clarithromycin can be detected by either the standard 14-day susceptibility testing or by detection of the erm (41) gene with up to 80% of M abscessus subsp abscessus carrying a functional erm (41) gene, in comparison to subspecies massiliense, which has a nonfunctional erm (41) gene [7, 10, [107] [108] [109] . As a result, identifying the organism to the subspecies level may be important for certain infections. If the organism is macrolide susceptible and is subspecies massiliense, a macrolide should be included in the drug regimen.
The antimicrobial regimen is usually guided by drug susceptibility testing results. The CLSI recommends susceptibility testing for the following antimicrobials: amikacin, cefoxitin, clarithromycin, ciprofloxacin, doxycycline, imipenem, linezolid, moxifloxacin, trimethoprim-sulfa, and tobramycin [9] . The only proven drugs for treatment of M abscessus are IV amikacin (in the absence of mutational resistance), cefoxitin, imipenem, and the macrolides (in the absence of a mutation and a functional erm(41) gene) [110] . Mycobacterium abscessus is frequently susceptible to amikacin, cefoxitin, clarithromycin, and imipenem, but this pattern varies greatly among locations. In addition, there is evidence of in vitro activity for rifabutin and clofazimine against M abscessus [111, 112] . Clofazimine, in particular, has been shown to have excellent in vitro activity against this pathogen and is being used with increasing frequency; however, its use is controversial because there are extremely limited data on its use in patients with M abscessus disease. It is available in the United States only via an Investigational New Drug from the US Food and Drug Administration (FDA) [1, [112] [113] [114] . A case series in South Korea of 42 adults without CF with M abscessus lung disease found that, in those who were administered clofazimine in combination with other antibiotics, 81% had improvement in symptoms and 31% had a radiographic response, with 24% converting to culture-negative sputum samples [112] . In addition, liposomal nebulized amikacin, although not FDA approved, is available for compassionate use, and IV amikacin is being given via nebulizer and has demonstrated some benefits in refractory patients [13] . A multicenter study of M abscessus pulmonary disease in CF patients found that there is frequently in vitro resistance to fluoroquinolones with 97% and 90% of isolates resistant to ciprofloxacin and moxifloxacin, respectively. This study also demonstrated high levels of resistance to doxycycline (98%), minocycline (98%), and trimethoprim-sulfamethoxazole (96%) [115] . However, a study of 55 isolates from patients with M abscessus pulmonary disease in China found higher rates of susceptibility to fluoroquinolones (41%-78%), sulfamethoxazole (75%), minocycline (44%), and doxycycline (34%) [116] . At Texas Children's Hospital in Houston, Texas, the majority of isolates are resistant to macrolide antibiotics, and many isolates have only intermediate susceptibility to imipenem and cefoxitin. Medications used to treat M abscessus can be difficult to tolerate and cause significant adverse effects. A study of adults in Korea showed that more than half of patients receiving cefoxitin had adverse effects, including neutropenia and hepatotoxicity, requiring discontinuation of therapy [110] .
Newer agents with activity against M abscessus include linezolid, tigecycline, and bedaquiline. Linezolid inhibits approximately 50% of isolates [115] ; however, long-term use has been associated with significant bone marrow suppression and peripheral neuritis [117] . Tigecycline is a glycin with good activity against M abscessus, although use of this medication has been associated with significant nausea, vomiting, and pancreatitis [118, 119] . Bedaquiline is an oral diarylquinoline approved for treatment of multidrug-resistant tuberculosis by the FDA in 2012. A study of in vitro activity of M abscessus isolates from China found that only 20% of isolates were resistant, and the mechanism of resistance is due to mutations in the atpE gene [120] . In a case series of 10 adults with pulmonary NTM infection (4 with M abscessus) treated with bedaquiline in addition to other antimycobacterial agents as salvage therapy, 90% had symptomatic improvement and 40% had radiographic improvement. However, the majority of patients experienced adverse events including nausea, arthralgias, and anorexia [121] . Unfortunately, there are minimal data on the long-term use and appropriate dosing of these medications in the pediatric population.
Surgical Therapy: General Principles
Based on expert opinion and case series, surgical therapy should be considered an important adjunct of management, depending on the extent and location of the infection. Debridement or incision and drainage of abscesses and infected tissues, when possible, and removal of infected medical devices and foreign bodies are essential aspects of management [15, 122] . Some adult patients with skin and soft tissue, CNS and ocular infections, and children with dental infections complicated by mandibular osteomyelitis and cervicofacial lymphadenitis have required surgical debridement in combination with antimicrobial therapy to effect a cure [3, 27, 32, 49, 104, 105, 123] . Most data on utility of surgical resection is for adult patients with lung disease. Although data are limited, adult patients with M abscessus focal lung disease have significantly improved outcomes with a combined surgical-medical approach [124] . Studies in patients with focal lung disease who do not have CF have demonstrated culture conversion rates in sputum after surgical resection of 65%-70%, higher than with antimicrobial therapy alone [124, 125] .
Management of Skin and Soft Tissue Infections
There are no standard treatment guidelines for management of skin and soft tissue infections caused by M abscessus, and, based on expert opinion, therapy should be guided by drug susceptibility results from the culture [126] . Treatment usually involves combination antimycobacterial therapy for 4-6 months [15, 127] . Surgical management with removal of infected foreign bodies and/or medical devices and debridement of abscesses or extensive soft tissue disease is critical to treatment of infection [1, 15, 122] . We recently cared for a patient with M abscessus VP shunt infection complicated by extensive skin and soft tissue infection affecting the entire shunt tract. Despite several months of appropriate antimycobacterial therapy, he did not achieve culture negativity until he underwent extensive surgical debridement of the entire shunt tract.
Management of Lymphadenitis
There are minimal data on the optimal management of M abscessus lymphadenitis in children. All data come from case reports and case series. In the dental outbreak in Georgia, 8 patients developed submandibular and/or cervical lymphadenitis, all of whom underwent excision of the involved nodes. Among these children, 4 underwent surgical resection alone, and 4 children, who were deemed to have inadequate surgical debridement, were also treated with combination antimycobacterial therapy [49] . All 8 children had resolution of disease. A single case report demonstrated cure of infection with azithromycin and pyrazinamide [128] . Although evidence is lacking for management of M abscessus lymphadenitis, similar to lymphadenitis due to other NTM, it is possible that surgical resection may speed recovery and possibly improve cosmetic outcomes. Regardless of the extent of surgical debridement, combination antimycobacterial therapy always should be considered.
Management of Intravenous Catheter Infections
There have been no randomized controlled trials to guide antimicrobial choice and treatment duration. All data presented here are based on case series. If no significant secondary infection has occurred, antimycobacterial therapy is usually given for several months. Combination therapy in adults has been shown to be superior to monotherapy. Combination therapy with at least 2 agents including an aminoglycoside, a fluoroquinolone, and/or a macrolide as well as immediate removal of intravascular catheters in adults is recommended [95] . If the organism is subspecies massiliense and macrolide-susceptible, a macrolide should be used as part of the regimen. In a review of pediatric oncology patients with catheter-associated infections due to rapidly growing NTM, there was a strong association with local debridement and cure in conjunction with combination antimicrobial therapy [97] .
Management of Central Nervous System Infections
There are very limited data-mostly case reports-on optimal management of M abscessus CNS infections. A particularly challenging aspect of treating M abscessus CNS infections is the need for adequate penetration of the antibiotics into the CSF. Based on the limited data available, patients should receive combination therapy with 2 or 3 antibiotics based on the drug susceptibility of the organism; at least one of these should be parenterally administered. This typically consists of therapy with amikacin, cefoxitin, imipenem, or a fluoroquinolone for at least 12 months [99] . Clarithromycin-based therapy should be used if the patient has subspecies massiliense. However, amikacin and macrolides have poor CNS penetration [123] . Among the newer drugs used to treat M abscessus infection, linezolid and clofazimine penetrate the CNS well, but tigecycline does not [129, 130] . In addition to combination antimycobacterial therapy, any infected foreign bodies or medical equipment, such as implanted catheters or VP shunts, should be removed [15, 34] .
Several case reports document successful use of intraventricular/intrathecal amikacin in addition to 2 to 3 intravenous and oral antimycobacterial drugs as a part of therapy for CNS infection [33, 34, 99, 102] . Our patient with VP shunt infection required 2 months of intraventricular amikacin therapy in addition to 3 IV agents to eradicate the CNS infection; unfortunately, deafness is a very common adverse effect of prolonged intraventricular aminoglycoside therapy. Doses of intraventricular amikacin in adult studies have ranged from 5 to 50 mg. The optimal duration of therapy is not known [131] .
Management of Ocular Infections
Based on expert opinion, case series, and reviews, therapy typically consists of a combination of both topical and intravenous antimicrobial treatment, guided by drug susceptibility results, with surgical debridement and removal of infected tissue as possible [104, 105, 123] . Antimycobacterial therapy typically consists of an intravenous aminoglycoside and a macrolide in addition to a topical fluoroquinolone [104] . Treatment duration should be guided by clinical response. A review of ocular infections due to M abscessus found that the mean duration of therapy required was approximately 5 months [104] . In addition to antimycobacterial and surgical therapy, treatment should include discontinuation of any topical corticosteroids [123] .
Management of Pulmonary Disease in Non-Cystic Fibrosis Patients
Pulmonary disease secondary to M abscessus in both adults and children tends to progress slowly and is more difficult to treat than disease due to other NTM. Because M abscessus is intrinsically resistant to numerous antimicrobials, there are limited treatment options [2] . The decision to initiate therapy should depend on each individual patient, weighing the risks and benefits of therapy [1] . Although there have been no published randomized controlled trials to determine optimal treatment, typical therapy for both adults and children consists of a combination of intravenous agents, such as amikacin with cefoxitin, and an oral macrolide for 2-4 months duration [1] . However, the use of an oral macrolide is now more controversial, given the possibility of a functional erm (41) gene that would cause macrolide resistance [132, 133] .
The goal of therapy for both adults and children when pulmonary disease is not localized, and/or surgical resection is not possible, is often clinical improvement as opposed to microbiologic cure [1, 132] . Studies assessing long-term outcomes have demonstrated a variety of cure rates, and all of the studies have analyzed adult patients. In one Korean study of patients with focal lung disease, most patients had symptomatic and radiographic improvement, although approximately one quarter of the patients required surgical resection [110] . In a study from National Jewish Health, 48% of patients experienced culture conversion, and there was a significant improvement in cure rates for patients who underwent surgical resection (57% for those who had surgical resection vs 28% for those who did not) [124] . Eradication has been documented in a pediatric patient with asthma and bronchiectasis who was treated with intravenous tigecycline, oral azithromycin, and inhaled tobramycin for 5 months [134] .
Patients With Cystic Fibrosis
There have been no published randomized controlled trials comparing antimicrobial regimens for treatment of M abscessus infection in patients with CF, and, thus far, no antibiotic strategy has been demonstrated to reliably produce long-term eradication of the organism in this population [1, 135] . The focus of therapy is usually on suppression to provide clinical improvement, improved pulmonary function, and slower progression of lung disease [1] .
All recommendations in the Cystic Fibrosis Foundation and the European Cystic Fibrosis Society guidelines are based on expert consensus [43, 53] . Combination therapy is recommended, and monotherapy should never be used for treatment. The Cystic Fibrosis Foundation and the European Cystic Fibrosis Society recommend subspeciation of all M abscessus isolates. Current therapy recommendations include an intensive phase of therapy followed by a continuation phase. The recommendations for the intensive phase are based on a consensus vote in which 83% of participants determined that this phase should consist of intravenous amikacin and an oral macrolide in addition to 1 or more of the following: intravenous tigecycline, imipenem, or cefoxitin. The duration of the intensive phase is usually 3-12 weeks, depending on severity of the infection and clinical response (Figure 2 ) [43, 53] . The use of tigecycline in adult patients has shown particularly promising results, with >60% of patients experiencing clinical improvement [119] . The recommended continuation phase is based on a consensus vote in which 89% of participants agreed. This phase consists of an oral macrolide and inhaled amikacin with 2 or 3 of the following oral options: minocycline, clofazimine, moxifloxacin, or linezolid. Unfortunately, most of these oral options have no proven activity against M abscessus infections. Optimal total duration of therapy is not known [43, 53] . As long as the isolate is macrolide susceptible, an oral macrolide is considered a backbone of therapy for these patients. Azithromycin is the preferred oral macrolide because clarithromycin is a stronger inducer of erm (41) [136] . However, there is some concern about this continuation phase: if a functional erm (41) gene is present, thus conferring resistance to the macrolides, and there is the typical resistance to the other oral medications, the patient would essentially be receiving monotherapy with inhaled amikacin.
Inhaled amikacin is used in the continuation phase due to the lack of oral options, and it has also been used for treatment of refractory disease. A recent randomized trial of inhaled liposomal amikacin for treatment of nontuberculous mycobacterial lung disease in patients both with and without CF resulted in improvements in sputum conversion and 6-minute walk distance [13] . However, because liposomal nebulized amikacin is not FDA approved, IV amikacin is being given via nebulizer, which has demonstrated some benefits in refractory patients [131] . Although limited systemic toxicity occurred with nebulized liposomal amikacin, the majority of patients experienced adverse events including dysphonia, bronchiectasis exacerbation, cough, and oropharyngeal pain [13] . Use of inhaled amikacin also has been associated with hemoptysis, ototoxicity, and vertigo [137] . Other treatment options have been associated with significant toxicities as well. Tigecycline can cause significant nausea, emesis, and pancreatitis, and in one study >90% of patients experienced adverse events [118, 119] . Linezolid can cause pancytopenia, peripheral neuropathy, and optic neuritis [117] . Table 1 shows potential antimicrobial choices and dosing regimens recommended for treatment of pulmonary M abscessus by the Cystic Fibrosis Foundation and European Cystic Fibrosis Society. It is important to emphasize that certain antibiotics, including trimethoprim-sulfamethoxazole, moxifloxacin, or minocycline, are likely to be effective only if they are found to be susceptible using standardized CSLI-approved methods. In addition, in recent years, some experts have expressed reluctance to recommend 3 times daily regimens for treatment of pulmonary M abscessus because most children are at school during the midday dose. Finally, there has been increasing use of once-daily 10 mg/kg IV or oral dosing of linezolid because the bone marrow suppression associated with administration of linezolid appears to be dose related [138] .
Lung Transplantation
Mycobacterium abscessus infection in adult patients with CF after lung transplantation is associated with increased morbidity and mortality [71, 72] . In a study evaluating patients with end-stage lung disease from CF who were candidates for lung transplantation, or previous recipients of a lung transplant, prevalence rates of NTM were approximately 20% for candidates and approximately 14% for recipients. Of patients who grew NTM before transplant, few developed NTM pulmonary disease posttransplant; of those who developed NTM pulmonary disease, the majority were due to M abscessus, and those patients experienced significant morbidity. Although infection with M abscessus was associated with morbidity, it did not affect overall survival [139] . Another study of 5 pediatric patients with M abscessus who received bilateral lung transplants demonstrated that outcomes may vary depending on the subspecies. None of the patients with subspecies massiliense or bolletii re-grew these organisms posttransplant, whereas 1 of 3 patients with subspecies abscessus experienced significant morbidity and 1 patient died [140] . A multinational study evaluating adult patients with a variety of underlying lung pathologies found that 17 of 5200 patients who received a lung transplant had M abscessus after transplantation. The majority of these 17 patients had disease localized to either the lungs or skin and soft tissue. There were 2 patients who had recurrence of infection; the other 15 first developed infection after transplantation. Two of the 15 patients with new infection posttransplant died secondary to their infection [141] . Despite an unpredictable course and potential for recurrence, the presence of M abscessus should not be considered an absolute contraindication to lung transplantation, although patients should initiate medical treatment before listing [43, 53, [140] [141] [142] . However, there are no specific guidelines for pretransplant management. Based on expert opinion, eradication of M abscessus infection should be attempted before transplant, meaning 3 negative sputum samples for more than 1 year. When clearance cannot be achieved, or when transplantation cannot be delayed, therapy should be initiated before transplantation and There are minimal data for pediatric dosing for treatment of M abscessus pulmonary infections in patients with cystic fibrosis. Suggested dosing per expert opinion are detailed above [53] .
continued for at least 6 weeks posttransplant. In addition, continued monitoring for M abscessus pulmonary disease and wound infection should be undertaken, because these patients are at particularly high risk for postoperative wound infection. Given the potential for one lung to act as a reservoir of infection, for patients with M abscessus pulmonary disease, bilateral lung transplantation should be considered [142] .
Other Adjunctive Therapies
Interferon-γ
Children and adults with mutations in the IFN-γ receptor are at increased risk for severe infections with mycobacteria [143] [144] [145] [146] , and although there are limited data, adjuvant therapy with IFN-γ may help treat those with refractory or disseminated disease regardless of the presence of IFN-γ receptor defects [147, 148] . There are no randomized controlled trials to evaluate the use of IFN-γ therapy for patients with disseminated disease, although there is a case report of a patient without evidence of IFN-γ receptor defects, as well as a case series of 7 patients with susceptibility to mycobacterial infections demonstrating its utility for refractory, disseminated disease [147, 148] . There are also 2 case reports (1 patient with functional IFN-γ deficiency and 1 with human immunodeficiency virus infection) demonstrating utility of aerosolized INF-γ therapy in clearance of NTM lung infections [149, 150] . There are no studies specific to M abscessus.
Corticosteroids
The use of corticosteroids as adjunctive therapy for NTM pulmonary disease is controversial, because there is some evidence that their use predisposes to disease and some evidence that their use may help treat disease by diminishing inflammation. They may hasten recovery from NTM infection based on a case series of immunocompetent patients with presumed hypersensitivity pneumonia secondary to NTM; however, none of these patients had M abscessus [1] . There is a single case report of an adult patient with M abscessus lung infection clinically improving after the addition of corticosteroid therapy to antimycobacterial therapy [151] . However, there is also evidence for risk of disseminated NTM disease with chronic corticosteroid use, as well as evidence for increased risk of pulmonary NTM with inhaled corticosteroid use [64] [65] [66] . A short-term course of corticosteroid therapy may be considered in patients with isolated lung disease and a hypersensitivity pneumonia presentation, whereas long-term corticosteroid therapy otherwise should be avoided [1] .
CONCLUSIONS
Although M abscessus infections are uncommonly encountered in children, they appear to be increasing in frequency in certain populations and can cause significant morbidity and mortality. Based on limited current knowledge, almost exclusively derived from studies on adult patients and expert opinion, long-term combination antimicrobial therapy guided in part by drug susceptibility results and surgical debridement of diseased tissue are mainstays of treatment. Treatment regimens can be difficult to tolerate, because many of the antimycobacterial drugs can cause significant adverse events, and duration of therapy is often prolonged. Further studies regarding epidemiology and risk factors, clinical presentation, optimal treatment, and outcomes in children are necessary.
